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REGULATION OF TUMOR GROWTH  
BY CHOP CHEMOTHERAPY-GENERATED DEBRIS 
DJANIRA FERNANDES 
ABSTRACT 
While CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and 
prednisone), the current standard of care for non-Hodgkin lymphoma (NHL), kills tumor 
cells, the accumulation of tumor cell “debris” can stimulate inflammation and tumor 
growth. Thus, cytotoxic cancer therapies are a double-edged sword. Previous studies have 
shown that apoptotic debris stimulates tumor growth. We hypothesize that (1) CHOP-
generated tumor cell debris can promote lymphoma progression via release of pro-
inflammatory cytokines; (2) blocking phosphatidylserine (PS), which is presented on the 
surface of apoptotic cells, may inhibit debris-stimulated cancer progression. Methods: 
Lymphoma EL4 debris was generated by treating tumor cells with CHOP chemotherapy. 
EL4 debris was isolated via Ficoll gradient and co-injected with living EL4 tumor cells 
into immunocompetent C57BL/6 mice. Macrophage-secreted cytokines were measured 
via array analysis. Results: Flow cytometry confirmed CHOP chemotherapy generated 
apoptotic/necrotic debris. Vincristine-, mafosfamide-, and prednisolone-generated 
lymphoma EL4 debris stimulated tumor growth by over 100-fold in a dose-dependent 
manner. Debris alone did not induce tumors, even at 250 days post-injection. 
Doxorubicin-generated EL4 debris stimulated tumor growth at low dose (1x105), but 
inhibited growth at high dose (9x105). Systemic administration of doxorubicin-generated 
EL4 debris or blocking PS in the cell debris generated by doxorubicin using annexin V or 
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an anti-PS neutralizing antibody inhibited doxorubicin-generated debris-stimulated tumor 
growth. Therapy-generated debris stimulated macrophage pro-inflammatory cytokine 
production. Conclusions: CHOP chemotherapy-generated debris regulates tumor growth 
via cytokine production. Thus, harnessing the anti-tumor activity of inhibitory debris or 
neutralizing PS on stimulatory debris may be a novel anti-cancer approach. 
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INTRODUCTION 
Cancer  
Cancer remains one of the leading causes of death in the United States and around 
the world. In 2017, it is estimated that there will be 1,688,780 new cancer cases and 
600,920 cancer deaths1. This is approximately 4,630 new cases and 1,650 deaths every 
day, or 3 new cases and 1 death per minute1. These statistics suggest the urgent need for 
new approaches and treatment options to combat the disease and one day find a cure for 
cancer.  
 
Hematological Cancers 
Hematological cancers, also known as blood cancers, are caused by abnormal 
production and/or function of blood cells, including white blood cells, red blood cells, 
and platelets. Hematological cancers originate within the bone marrow, where blood cells 
are produced, or in other blood-forming organs responsible for blood cell maintenance. 
Examples of hematological cancers include leukemia, multiple myeloma, and lymphoma. 
Leukemia is the overproduction of immature blood cells, usually white blood cells, in the 
bone marrow and in other blood-forming organs. Due to the rapid proliferation of cancer 
cells, leukemia cells gradually displace normal blood and marrow cells leading to anemia 
and hindering the body’s ability to fight infection. There are four main types of leukemia: 
acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic 
leukemia (ALL), and chronic lymphocytic leukemia (CLL). These four types of leukemia 
are distinguished based on where the cancer originates, the specific cancer cell type, and 
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the rate of cancer progression. Multiple myeloma originates in plasma or mature B cells. 
Plasma cells are responsible for producing antibodies that help the body attack foreign 
invaders. Patients with multiple myeloma are more prone to infections because they have 
compromised plasma cells. By contrast, lymphoma is a cancer of the lymphatic system 
that develops in lymphocytes. The lymphatic system is a network of tissues and organs 
responsible for transporting immune cells and waste products throughout the body via 
lymph fluid. It includes the lymph nodes, spleen, thymus gland, and bone marrow. As 
lymphatic tissue is found everywhere in the body, lymphoma can develop in various 
areas and metastasize to any organ. The two main types of lymphoma are Hodgkin 
lymphoma (HL) and non-Hodgkin lymphoma (NHL). HL and NHL are differentiated 
based on the presence of large, abnormal cells called Reed-Sternberg cells, which are 
primarily derived from B lymphocytes and are found in HL but not NHL43. Other 
differences between HL and NHL include the rate of cancer progression, organs affected, 
symptoms, and age of onset.  
 
While non-Hodgkin lymphoma is the seventh most common cancer among 
females and males in the United States, HL is less common1. In 2017, there is estimated 
to be 72,240 new cases of NHL and 20,140 deaths due to this type of cancer in the United 
States alone1. NHL incidence has risen steadily over the past decade, while the death rate 
has only decreased about 1% per year2 (Figure 1).  
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Figure 1. Number of non-Hodgkin lymphoma cases and deaths per 100,000 persons. 
The number of new cases of non-Hodgkin lymphoma was 19.5 per 100,000 men and 
women per year. The number of deaths was 6.0 per 100,000 men and women per year. 
Based on data from Surveillance, Epidemiology, and End Results Program (SEER) 1992-
20132.  
 
Current Therapy - CHOP Chemotherapy Regimen for Lymphoma 
Currently, there is no single effective therapeutic approach that can be used to 
treat all types of cancer. Treatment for cancer depends on many factors, including stage, 
affected areas and organs in which the cancer has metastasized to, and the specific type of 
cancer. Conventional cancer treatment includes surgery, radiotherapy, chemotherapy, 
targeted therapy, and/or hormone therapy. These treatments may be used alone or in 
combination depending on which regimen induces maximal tumor cell death and has 
minimal toxicity. Surgery is used to remove the cancerous tissue, while radiotherapy, 
through the use of x-ray radiation, destroys cancer cells at the site of the tumor. 
Chemotherapeutic agents are cytotoxic or cytostatic drugs designed to kill or slow the 
growth of tumors, respectively. Chemotherapy drugs non-specifically target rapidly 
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dividing cells such as cancerous cells. In addition to cancer cells, normal cells can also be 
damaged by radiation or chemotherapy. However, unlike cancer cells, normal cells are 
usually able to repair themselves, as they lack compromising mutations in cellular 
proliferation and DNA repair machinery. Hormone therapy utilizes targeted drugs that 
affect hormone signaling pathways, and is primarily used to treat cancer types that are 
sensitive to hormones, such as breast and prostate cancers.  
  
For non-Hodgkin lymphoma, there are currently four main therapies: 
chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Stem cell transplant 
and surgery are rarely considered to treat non-Hodgkin lymphoma, as it destroys the bone 
marrow, which is where new blood cells originate. This may cause life-threatening 
infections, bleeding, anemia, and other serious conditions due to low blood cell counts. 
CHOP chemotherapy, which consists of cyclophosphamide/mafosfamide (“C”), 
hydroxydaunorubicin (“H”), oncovin (“O”), and the steroid prednisone/prednisolone 
(“P”), is the most commonly used chemotherapy regime for NHL. In 1993, a pivotal 
study that compared CHOP with three other chemotherapy regimens (m-BACOD, 
ProMACE-CytaBOM, and MACOP-B) concluded that CHOP was the least toxic, yet 
exhibited a similar efficacy20. As a result, the CHOP regimen remains the conventional 
treatment for patients with NHL.  
 
Cyclophosphamide is an alkylating agent that binds to DNA forming cross-links 
that prevent DNA replication. Cyclophosphamide is metabolized in the liver into its 
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active form, mafosfamide.  Hydroxydaunorubicin (also known as doxorubicin or 
adriamycin) is an intercalating agent that inserts between bases of DNA and inhibits cell 
division. Oncovin (also known as vincristine) binds to the protein tubulin, preventing 
chromosome separation and thereby halting cell division. Prednisone is a corticosteroid 
that acts as an anti-inflammatory and immunosuppressive agent. It is modified in the liver 
to its active form, prednisolone, which is more readily absorbed by the body. Prednisone 
is given in the chemotherapy regimen to prevent possible allergic reactions and to treat 
the nausea and vomiting associated with the other three chemotherapy drugs. 
Cyclophosphamide, doxorubicin, and vincristine are administered intravenously to cancer 
patients on day 1 and prednisone is taken orally as a pill once a day for the first five days 
of the cycle (day 1-day 5). The cycle is repeated 6-8 times with a 3-week interval off 
therapy (Figure 2). 
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Figure 2. CHOP chemotherapy regimen for non-Hodgkin lymphoma patients. 
Cyclophosphamide, doxorubicin, and vincristine are given intravenously (IV) on day 1 
and the steroid prednisone is taken orally as a pill once a day for the first five days of 
each cycle. The cycle is repeated 6-8 times with a 3-week interval off therapy 
 
 
Tumor Cell Debris (Stimulatory or Inhibitory Tumor Cell Debris) 
Promotion of tumor growth by radiation-generated cell debris was first 
demonstrated by Dr. Laszlo Révész (Révész phenomenon) in 195654 and confirmed in 
follow-up reports for radiation-induced cell death in 201130 and 201521. Irradiated 
apoptotic cells in aggressive B cell lymphoma have been found to display oncogenic 
properties by promoting angiogenesis and recruiting macrophages that are involved in 
tissue-reparatory and growth-promoting processes such as angiogenesis and tissue 
remodeling21. This pro-tumorigenic effect is sustained by constitutive apoptosis that 
maintains a chronic inflammatory microenvironment for the tumor. Apoptotic tumor cells 
activate macrophage production of pro-inflammatory mediators39. 
 
THERAPY REGIMEN: 
 
Cyclophosphamide,  
Doxorubicin, Vincristine (IV) 
+ 
Prednisone  
(oral pill, first 5 days of cycle) 
 
 
Repeat therapy regimen for 
6-8 cycles 
 
3 weeks 
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By contrast, there are a larger number of reports that seek to demonstrate the 
opposite stance. Namely, that tumor cell debris generated by radiation, certain 
chemotherapeutics, HSVtk/GCV (Herpes simplex virus thymidine kinase/gancyclovir) 
system, photodynamic therapy or radiofrequency ablation, including ultrasound, results in 
the inhibition of tumor growth. The rationale is that debris stimulates the adaptive 
immune system, which provides the basis for developing cancer vaccines10,16,49. For 
instance, radiation- and ultrasound-generated tumor cell debris can activate dendritic cells 
to initiate a host-specific anti-tumor immune response10,16. In addition, tumor debris from 
radiofrequency ablation-mediated necrosis can also initiate anti-tumor immunity18. 
Furthermore, tumor cell debris generated by certain chemotherapeutic agents has been 
reported to stimulate the uptake of cell debris by dendritic cells to inhibit tumor growth 
via immunogenic cell death. These studies provide a basis for the generation of cancer 
vaccines and the stimulation of anti-neoplastic immune responses in vivo49,11. In 2011, a 
United States patent application was published that proposed the use of tumor cell debris 
to “reduce the recurrence of a tumor and/or inhibit or slow down the growth of a 
tumor”47. Cancer vaccines rely on the ability of the immune system to distinguish 
between normal physiological cell death and pathological cell death. Therefore, this 
differential response of the immune system can be used to generate tumor cell debris that 
inhibits or slows tumor growth.  
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Immunogenic and Non-Immunogenic Cell Death  
One factor that could account for whether debris stimulates or inhibits tumor 
growth is immunogenic versus non-immunogenic cell death. Non-immunogenic cell 
death (NICD) occurs when apoptotic cells evade immune detection and promote 
immunosuppression. NICD is often viewed as tolerogenic, meaning that it actively down-
regulates the anti-tumor immune response11. A classic marker of non-immunogenic cell 
death is phosphatidylserine (PS). Phosphatidylserine is a phospholipid component of the 
cell membrane that is externalized from the inner leaflet to the outer leaflet of the 
membrane as a cell is undergoing apoptosis. Externalized PS functions as an 
evolutionarily conserved immunosuppressive signal that promotes tolerance and prevents 
local and systemic immune activation8. As a result, PS signaling allows phagocytes to 
clear dead cells without alarming the immune system. PS is found to be highly 
dysregulated in the tumor microenvironment, as tumor cells can express PS to evade 
immune detection8. This suggests that blocking externalized PS on the chemotherapy-
generated debris could elicit an anti-tumor adaptive immune response.  
 
During immunogenic cell death (ICD), antigens on apoptotic cells elicit an anti-
tumor immune response via the adaptive immune system in which immune cells 
recognize the debris as foreign bodies, through the presentation of “non-self” antigens on 
the surface of dead/dying cells. The ensuing inflammatory response not only leads to 
debris clearance by phagocytes, such as macrophages, but also establishes a long-term 
immunological memory23. Chemotherapeutics known to induce this type of cell death 
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include doxorubicin, oxaliplatin, mitoxantrone, and bortezomib23. In response to these 
chemotherapies, the malignant cells have been shown to produce damage-associated 
molecular patterns (DAMPs), including exposure of calreticulin (CARL), secretion of 
adenosine triphosphate (ATP), release of high-mobility group box 1 (HMGB1) and 
Annexin A123. CARL is an endoplasmic reticulum chaperone protein that is exposed on 
the cell surface during ICD and acts as a phagocytic signal that stimulates antigen 
uptake23. HMGB1 is a chromatin protein that is released by the cell when it undergoes 
ICD and mediates pro-inflammatory signaling and dendritic cell maturation23. ATP 
released by dying cells elicits recruitment and activation of dendritic cells23. The role of 
DAMPs is to facilitate the uptake of generated debris by antigen-presenting cells 
resulting in an adaptive immune response. This response creates an immunological 
memory that can elicit a future anti-tumor immune reaction. As a result, DAMPs 
coordinate antigen-specific responses by acting on both the innate and adaptive immune 
system.   
 
Specific Aims  
The purpose of this study is to evaluate whether CHOP chemotherapy regulates 
tumor growth via therapy-generated tumor cell debris and associated inflammation, and 
to investigate the mechanism(s) underlying debris-mediated tumor growth. Initially, 
CHOP chemotherapy-generated debris was established in vitro with all four drugs 
separately and also in combination. The cell death profile of each debris was 
characterized via flow cytometry analysis. Then, the activity of each debris on tumor 
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growth and progression was studied in a debris-stimulated tumor model in vivo. These 
results demonstrate that CHOP chemotherapy-generated debris stimulates or inhibits 
tumor growth depending on the type of drug and the amount of debris. 
  
Tumor cell debris has been reported to be both pro- and anti-tumorigenic, 
depending on the type of debris and its surrounding microenvironment. One key factor 
that may account for this difference is immunogenic versus non-immunogenic cell death. 
Therefore, the role of CHOP chemotherapy-generated tumor cell debris to elicit an 
immune system response that stimulates or inhibits tumor growth will be evaluated. The 
associated inflammation and pro-inflammatory cytokine production by macrophages will 
be determined by exposing macrophages to immunogenic and non-immunogenic debris. 
This result will reveal the role of tumor cell debris in the tumor microenvironment by 
acting on immune cells, such as macrophages. 
 
Our laboratory has demonstrated that only apoptotic debris stimulates primary 
tumor growth. We next asked whether phosphatidylserine (PS), which is presented on the 
surface of apoptotic cells, could be a mediator of tumor growth. Previous studies have 
suggested that PS is dysregulated in the tumor microenvironment and acts as an 
immunosuppressive signal8. The potential therapeutic application of PS neutralization 
remains unharnessed. Therefore, we investigated the potential role of PS in debris-
stimulated tumor growth. Results from this study may offer a novel approach to cancer 
treatment by targeting CHOP chemotherapy-generated debris. 
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METHODS  
Cell Lines and Culture 
 
 The murine lymphoma cell line EL4 was obtained from the American Type 
Culture Collection (ATCC) (Manassas, VA). EL4 tumor cells were cultured in ATCC-
formulated Dulbecco’s Modified Eagle’s Medium (ATCC-DMEM) supplemented with 
10% horse serum and 1% penicillin-streptomycin-glutamine (GPS), and incubated at 
37°C with 5% carbon dioxide (CO2).  The murine macrophage cell line RAW264.7 was 
obtained from ATCC (Manassas, VA). RAW264.7 cells were cultured in ATCC-DMEM 
medium supplemented with 10% fetal bovine serum (FBS) and 1% GPS, and incubated at 
37°C with 5% CO2.  
Reagents and Compounds 
 The chemotherapeutic drugs doxorubicin, vincristine, and the steroid prednisolone 
were purchased from Sigma-Aldrich (Natick, MA), and the chemotherapeutic drug 
mafosfamide was purchased from Santa Cruz Biotechnology (Dallas, TX).  
Generation of EL4 debris by CHOP chemotherapy  
 Murine lymphoma EL4 tumor cell debris was generated in vitro for each CHOP 
chemotherapy drug. EL4 tumor cells were treated with complete media (ATCC-DMEM 
10% horse serum 1% GPS) plus 10 micromolar (µM) of doxorubicin for 24 hours, 20 µM 
of mafosfamide for 72 hours, 40 nanomolar (nM) of vincristine for 72 hours, 750 µM of 
prednisolone for 72 hours, or a combination of all four drugs (20 µM mafosfamide, 40 
nM vincristine, 325 µM prednisolone, and 0.5 µM doxorubicin) for 24 hours.    
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Flow Cytometry Analysis of Debris 
After EL4 tumor cells were treated with the appropriate dose of each CHOP 
chemotherapeutic drug or the combination of drugs for the appropriate duration (as 
described above), the whole cell population was collected. The cells were washed in PBS 
and prepared according to the FITC Annexin V/Dead Cell Apoptosis Kit protocol (Life 
Technologies, Carlsbad, CA). The proportion of apoptotic and necrotic cells was 
measured by staining with annexin V and propidium iodide (PI), respectively, and 
visualized using BD LSR Fortessa (J-Fortessa JF415). The data was analyzed using 
FlowJo software (Tree Star Inc). Viable cells stain annexin V-/PI-, apoptotic cells are 
annexin V+/PI-, necrotic cells are annexin V-/PI+, and late apoptotic and necrotic cells 
are annexin V+/PI+.  
Debris-Stimulated Tumor Model 
 All animal studies were reviewed and approved by the Animal Care and Use 
Committee of Beth Israel Deaconess Medical Center, Boston, MA. For the doxorubicin-
generated EL4 debris-stimulated tumor model, EL4 tumor cell debris was generated by 
doxorubicin as described. The whole cell population was collected and the dead cells 
were counted via trypan blue exclusion with a hemocytometer. The dead cell population 
was separated from the living cells via a Ficoll gradient (Life Sciences, Pittsburgh, PA). 
The debris was resuspended in PBS to give a final concentration of 1.8x107 cells/mL. 
Living EL4 tumor cells were collected, pelleted, and resuspended in PBS to give a final 
concentration of 2x105 cells/mL. Six-week old male C57BL/6 mice (Jackson laboratory, 
Bar Harbor, ME) were injected subcutaneously in the mid-dorsum with either 
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doxorubicin-generated EL4 debris alone (9x105 dead cells), a subthreshold inoculum of 
untreated EL4 tumor cells alone (1x104 living cells), or doxorubicin-generated EL4 tumor 
cell debris (9x105, 3x105, or 1x105 dead cells) co-injected with EL4 tumor cells (1x104 
living cells). This protocol was repeated for the other three CHOP chemotherapy drugs 
(mafosfamide, vincristine, and prednisolone). All mice were injected with a total volume 
of 100 µL PBS and cell suspension. 
Tumor Inhibition Model 
EL4 tumor cells were treated with doxorubicin as described above. Then, the 
whole cell population was collected and the debris was separated from the living cells via 
a Ficoll gradient. The debris was resuspended in PBS to give a final concentration of 
1.8x107 cells/mL. Living EL4 tumor cells were collected, pelleted, and resuspended in 
PBS to give a final concentration of 2x107 cells/mL. Six-week old male C57BL/6 mice 
were injected subcutaneously with either untreated EL4 tumor cells alone (1x105 or 5x105 
living cells), or a combination of doxorubicin-generated debris (9x105 dead cells) with 
EL4 tumor cells (1x105 or 5x105 living cells). 
Intraperitoneal Debris Injections   
 Murine lymphoma EL4 tumor cells were treated with doxorubicin as described 
above. The whole cell population was collected and the dead cells were separated from 
the living cells via a Ficoll gradient. The debris was resuspended in PBS to give a final 
concentration of 18x106 cells/mL. Living EL4 tumor cells were collected, pelleted, and 
resuspended in PBS to give a final concentration of 2x105 cells/mL. Mice were injected 
subcutaneously with a combination of doxorubicin-generated debris (1x105 dead cells) 
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and a subthreshold inoculum of EL4 tumor cells (1x104 living cells). The doxorubicin-
generated EL4 tumor cell debris was prepared for daily intraperitoneal (IP) injections as 
described above and resuspended in PBS to give a final concentration of 9x106 cells/mL. 
The resuspended debris was aliquoted and stored at -20°C. Starting on day of injection, 
mice were systemically treated with 9x105debris/100 µL/day via IP injections for 30 
days.  
Analysis of Macrophage-secreted Cytokines  
 RAW264.7 murine macrophages were plated in 6-well plates at 2x106 cells per 
well and incubated for 3 hours at 37℃. Murine lymphoma EL4 tumor debris was 
prepared as described above. The whole cell population was collected and the debris was 
separated via a Ficoll gradient. The debris was resuspended in PBS to give a final 
concentration of 40x106 cells/mL. The tumor cell debris was added to the macrophages at 
a 1:4 macrophage: tumor cell ratio for 1 hour. The wells were aspirated and the 
macrophages were re-fed with 3 mL serum-free ATCC-DMEM (1% GPS) per well. 
Plates were incubated for 24 hours at 37℃. Conditioned media from each well was 
pelleted, collected, and used according to the protocol provided by the R&D Systems 
Proteome Profiler: Mouse Cytokine Array Panel A kit (Minneapolis, MN).  
Annexin V and Anti-Phosphatidylserine Mechanism  
 Unlabeled Annexin V recombinant protein (Affymetrix eBioscience, Waltham, 
MA) was reconstituted in 1 mL distilled water and stored at -20℃. EL4 tumor cell debris 
was generated by doxorubicin as described above. Dead cells were isolated via Ficoll 
gradient and resuspended in 10 µM of Annexin V to give a final concentration of 1x106 
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cells/mL. Suspensions were incubated at room temperature for 1 hour. After 1 hour, the 
cells were pelleted and resuspended in PBS to give a final concentration of 1.8x107 
cells/mL. Living EL4 tumor cells were collected, pelleted, and resuspended in PBS to 
give a final concentration of 2x105 cells/mL. Six-week old male C57BL/6 mice were 
injected subcutaneously with either a combination of Annexin V-treated doxorubicin-
generated debris (9x105, 3x105, or 1x105 dead cells) and EL4 tumor cells (1x104 living 
cells), or a combination of untreated doxorubicin-generated debris (9x105, 3x105, or 
1x105 dead cells) and EL4 tumor cells (1x104 living cells).  
 Mouse monoclonal anti-phosphatidylserine (anti-PS) antibody was purchased 
from Millipore/Sigma (Natick, MA). EL4 tumor cell debris was generated by 
doxorubicin and collected as described above. The debris was resuspended at 1x106 
cells/mL with 2 µg/mL of anti-PS antibody and incubated for 1 hour at 4℃. After one 
hour, the debris was pelleted and resuspended in PBS to give a final concentration of 
1.8x107 cells/mL. Living EL4 tumor cells were collected, pelleted, and resuspended in 
PBS at a concentration of 2x105 cells/mL. Mice were injected with either a combination 
of anti-PS-treated doxorubicin-generated tumor cell debris (9x105 or 3x105 dead cells) 
and EL4 tumor cells (1x104 living cells), or a combination of untreated doxorubicin-
generated debris (9x105 or 3x105 dead cells) and EL4 tumor cells (1x104 living cells).  
Statistical Methods  
 Student’s two-sided unpaired t test was used to analyze the difference between 
two groups. P value less than 0.05 were considered statistically significant. Data are 
presented as mean ±  standard error of the mean (SEM).   
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RESULTS 
CHOP chemotherapy generates lymphoma tumor cell debris  
CHOP chemotherapy-generated EL4 lymphoma tumor cell debris was 
characterized by flow cytometry analysis and cell death was validated via staining for 
apoptotic and necrotic cells. Annexin V is an apoptotic cell marker that binds to 
phosphatidylserine (PS), which is externalized from the inner leaflet to the outer leaflet of 
the plasma membrane when a cell is undergoing apoptosis. Propidium iodide (PI) is a 
necrotic marker that binds to DNA. Flow cytometry analysis of doxorubicin-treated EL4 
tumor cells demonstrated 95.3% total cell death (57.9% apoptotic cells (annexin V+PI-), 
0.1% necrotic cells (annexin V-PI+), and 37.3% late apoptotic and necrotic cells (annexin 
V+PI+)) (Figure 3a). Mafosfamide-treated EL4 tumor cells resulted in 85.5% total cell 
death (76.6% apoptotic cells, 0.20% necrotic cells, and 8.65% late apoptotic and necrotic 
cells) (Figure 3b). Vincristine-treated EL4 tumor cells generated 78.8% total cell death 
(Figure 3c). Prednisolone-treated EL4 tumor cells showed 88.4% total cell death (85.1% 
apoptotic cells, 0.42% necrotic cells, and 2.80% late apoptotic and necrotic cells) (Figure 
3d). EL4 tumor cells treated with a combination of all four drugs of CHOP (20 µM 
mafosfamide, 40 nM vincristine, 325 µM prednisolone, and 0.5 µM doxorubicin) for 24 
hours resulted in 93.2% total cell death (2.3% apoptotic cells, 46.4% necrotic cells, and 
44.4% late apoptotic and necrotic cells) (Figure 3e). Taken together, each of the CHOP 
chemotherapy drugs and the combination generated significant EL4 tumor cell debris.  
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Figure 3 
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Figure 3. CHOP chemotherapy generates tumor cell debris. Lymphoma tumor cells 
(EL4) were incubated with (a) 20 µM mafosfamide, (b) 10 µM doxorubicin, (c) 40 nM 
vincristine, (d) 750 µM prednisolone, (e) a combination of all four drugs, or vehicle. Cell 
death was confirmed by flow cytometry analysis (annexin V+ (apoptotic cells), annexin 
V+/PI+ (late apoptotic and necrotic cells), and PI+ (necrotic cells)). Mafosfamide, 
doxorubicin, vincristine, prednisolone, and CHOP combination treatment generated 
85.5%, 95.3%, 78.8%, 88.4%, 93.2% total cell death, respectively. Red arrow represents 
the dose that was selected to generate EL4 tumor cell debris. *p≤0.05, **p≤0.001, 
***p≤0.0001 vs. control. 
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CHOP chemotherapy-generated debris regulates lymphoma tumor growth  
To assess whether CHOP chemotherapy-generated lymphoma EL4 tumor cell 
debris stimulates tumor growth, we developed a debris-stimulated tumor model. Tumor 
cell debris was generated in vitro by treating EL4 tumor cells with CHOP chemotherapy, 
and the resulting dead cells were co-injected with a subthreshold inoculum of living 
tumor cells (1x104 living cells) into mice. The amount of living cells in the subthreshold 
inoculum does not induce a growing tumor in the mice and is thus representative of a 
dormant tumor. Co-injecting increasing amounts of vincristine-generated EL4 tumor cell 
debris (1x105, 3x105, 9x105, or 1.8x106 dead cells) with a subthreshold inoculum of EL4 
tumor cells (1x104 living cells) stimulated tumor growth in a dose-dependent manner 
(Figure 4a). Injecting mice with vincristine-generated EL4 tumor cell debris without 
living cells did not induce tumor growth, even at 250 days post injection. Mafosfamide-
generated EL4 tumor cell debris also demonstrates a dose-dependent stimulation of tumor 
growth when co-injected with a subthreshold inoculum of EL4 tumor cells (1x104 living 
cells) (Figure 4b). Similarly, prednisolone-generated EL4 tumor cell debris co-injected 
with a subthreshold inoculum of EL4 tumor cells stimulated tumor growth in a dose-
dependent manner (Figure 4c). In contrast, when the highest amount of doxorubicin-
generated EL4 tumor cell debris (9x105 dead cells) was co-injected with the subthreshold 
inoculum of living cells, none of the mice exhibited visible tumors. Interestingly, the 
lowest amount of doxorubicin-generated EL4 tumor cell debris (1x105 dead cells) 
stimulated rapid and aggressive tumor growth by 20 days post-injection (Figure 4d). 
Thus, CHOP chemotherapy-generated debris regulates lymphoma tumor growth. 
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Figure 4 
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Figure 4. CHOP chemotherapy-generated debris regulates tumor growth. Debris-
stimulated tumor growth from (a) vincristine-, (b) mafosfamide-, (c) prednisolone-, and 
(d) doxorubicin-generated EL4 tumor cell debris co-injected with a subthreshold 
inoculum of EL4 living cells (1x104 living cells). n=4-5 mice per group. *p≤0.05, 
**p≤0.001, ***p≤0.0001 vs. living EL4 tumor cells alone. 
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Doxorubicin inhibits primary tumor growth 
 We next evaluated whether doxorubicin-generated EL4 tumor cell debris could 
inhibit primary lymphoma tumor growth at a higher inoculum of living EL4 tumor cells. 
EL4 tumor cells alone (1x105 or 5x105 cells) induced aggressive growing tumors in mice. 
While doxorubicin-generated EL4 tumor cell debris (9x105 dead cells) co-injected with 
living EL4 tumor cells (5x105 living cells) did not significantly inhibit tumor growth, 
doxorubicin-generated EL4 tumor cell debris co-injected with 1x105 living EL4 tumor 
cells significantly inhibited tumor growth compared to 1x105 living tumor cells alone 
(Figure 5). In fact, 3 out five mice exhibited no visible tumors. This is consistent with 
previous reports that immunogenic cell death via doxorubicin inhibits tumor growth11. 
Thus, 9x105 doxorubicin-generated EL4 tumor cell debris inhibited primary tumor 
growth when co-injected at a 1:9 ratio of living EL4 tumor cells: doxorubicin-generated 
EL4 tumor cell debris.  
 
Figure 5. Doxorubicin-generated debris inhibits primary tumor growth. Tumor 
growth in mice co-injected with doxorubicin-generated EL4 tumor cell debris and 1x104 
or 5x105 EL4 living tumor cells. n=4-5 mice per group. *p≤0.05 vs. EL4 living cells 
alone  
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Systemic doxorubicin-generated debris inhibits tumor growth  
We next evaluated the inhibitory activity of doxorubicin-generated EL4 tumor 
cell debris when administered systemically to tumor-bearing mice. First, the mice were 
co-injected with doxorubicin-generated EL4 tumor cell debris (1x105 dead cells) and a 
subthreshold inoculum of EL4 tumor cells (1x104 living cells). This combination 
stimulates aggressive debris-mediated tumor growth (Figure 4d). Daily systemic IP 
treatment with doxorubicin-generated EL4 tumor cell debris (9x105 dead cells) inhibited 
tumor growth compared to mice that did not receive the systemic treatment with 
doxorubicin-generated EL4 debris (Figure 6). Notably, none of the mice had any visible 
tumors compared to control mice up to 30 days post injection. Therefore, systemic 
administration of doxorubicin-generated EL4 debris mimics an anti-tumorigenic vaccine.  
 
Figure 6. Systemic doxorubicin-generated debris inhibits tumor growth. Systemic 
intraperitoneal administration of doxorubicin-generated EL4 tumor cell debris (9x105 
dead cells) inhibits primary tumor growth. On day 0, debris-stimulated tumors were 
generated subcutaneously by co-injecting 1x105 doxorubicin-generated EL4 tumor cell 
debris with 1x104 living tumor cells. n=4-5 mice per group. *p≤0.05 vs. control.   
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CHOP chemotherapy stimulates macrophage cytokine production 
Next, we investigated whether CHOP chemotherapy-generated EL4 tumor debris 
could stimulate inflammation in the tumor microenvironment via debris-stimulated 
macrophage production of pro-inflammatory cytokines/chemokines. RAW264.7 
macrophages were exposed debris generated by each CHOP chemotherapy drug and the 
combination of all four CHOP drugs. Cytokine screening of conditioned media from 
macrophages demonstrated an increase in pro-inflammatory cytokine release by 
macrophages co-cultured with tumor cell debris (generated by mafosfamide, vincristine, 
prednisolone, and the combination), including sICAM-1/CD54, CCL2/MCP-1, MIP-
2/CXCL2, RANTES/CCL5 and TNF-α, compared to macrophages alone (Figure 7). 
Intriguingly, doxorubicin-generated EL4 tumor cell debris stimulated macrophage 
secretion of the anti-tumorigenic cytokine IL-1ra compared to macrophages alone. Thus, 
CHOP chemotherapy-generated EL4 tumor cell debris stimulates macrophage secretion 
of one anti-tumorigenic and at least five critical pro-tumorigenic cytokines. 
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Figure 7. CHOP chemotherapy stimulates macrophage pro- and anti-tumorigenic 
cytokine production. CHOP chemotherapy-generated EL4 tumor cell debris increases 
macrophage secretion of pro- and anti-inflammatory cytokines/chemokines. 
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inoculum of annexin V-treated doxorubicin-generated EL4 tumor cell debris (3x105 dead 
cells) was co-injected with the subthreshold inoculum of EL4 tumor cells (1x104 living 
cells) tumor growth was stimulated in every mouse (blue curve) compared to control 
mice which exhibited no apparent tumor growth (orange curve) (Figure 8). When annexin 
V-treated or untreated doxorubicin-generated EL4 tumor cell debris (9x105 dead cells) 
was co-injected with the subthreshold inoculum of EL4 tumor cells (1x104 living cells), 
zero out of five mice grew tumors (Figure 8 – orange curve). This suggests that the tumor 
inhibitory activity of 9x105 doxorubicin-generated debris could not be neutralized by 10 
µM annexin V. Therefore, annexin V diminishes the stimulatory activity of 1x105 
doxorubicin-generated debris, while neutralizing the inhibitory activity of 3x105 
doxorubicin-generated debris.  
 
Figure 8. Annexin V neutralizes doxorubicin-generated EL4 debris-mediated tumor 
growth. Debris-stimulated EL4 tumor growth from annexin V-treated doxorubicin-
generated EL4 tumor cell debris (1x105 or 3x105) co-injected with a subthreshold 
inoculum of living EL4 tumor cells (1x104). n=5 mice per group. *p≤0.05 vs. respective 
untreated dead cells + EL4 living cells.    
0 
500 
1000 
1500 
2000 
2500 
0 10 20 30 40 
Tu
m
or
 V
ol
um
e 
(m
m
3 ) 
 
Days Post Injection 
3 x 105 dead cells 
9 x 105 dead cells +/- Annexin V  
1 x 105 dead cells  
+ EL4  
living cells 
(1 x 104) 
1 x 105 dead cells 
+ Annexin V 
3 x 105 dead cells 
+ Annexin V 
*"
	  27 
Anti-phosphatidylserine neutralizes tumor growth inhibited by doxorubicin-
generated debris  
 Next, we probed whether an anti-PS antibody would have the same activity as 
Annexin V in blocking PS-mediated tumor growth. Doxorubicin-generated EL4 tumor 
cell debris was treated in vitro with 2 µg/ml of anti-PS antibody prior to co-injection with 
living cells. Doxorubicin-generated EL4 tumor cell debris (3x105 or 9x105 dead cells) co-
injected with a subthreshold inoculum of EL4 tumor cells (1x104 living cells) did not 
stimulate tumor growth. By contrast, when anti-PS-treated doxorubicin-generated EL4 
tumor cell debris (3x105 dead cells) was co-injected with a subthreshold inoculum of EL4 
tumor cells (1x104 living cells), 5 out of 5 mice exhibited rapid tumor growth (Figure 9). 
Interestingly, when anti-PS-treated doxorubicin-generated EL4 tumor cell debris (9x105) 
was co-injected with a subthreshold inoculum of living EL4 tumor cells (1x104), zero out 
of 5 mice grew a tumor, suggesting that blocking PS alone is not sufficient to stimulate 
tumor growth in mice injected with the highest inoculum of doxorubicin-generated debris 
(9x105 dead cells). 
	  28 
Figure 9. Anti-phosphatidylserine neutralizes tumor growth inhibited by 
doxorubicin-generated debris. Anti-PS-treated doxorubicin-generated EL4 tumor cell 
debris co-injected with a subthreshold inoculum of living EL4 tumor cells (1x104 dead 
cells) stimulated tumor growth. n=5 mice per group. *p≤0.05 vs. control. 
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DISCUSSION 
Our project addresses the limitation of current cancer therapy involving cell death. 
For decades, cancer therapy including hematological cancer research has focused on the 
killing of cancer cells to reduce tumor burden. However, the tumor cell debris is an 
underappreciated component of the tumor microenvironment that promotes tumor 
progression. Therapy-generated debris accumulates in the tumor microenvironment, 
inducing inflammation that in turn stimulates tumor growth and progression. This chronic 
inflammatory microenvironment can be triggered when phagocytes, such as 
macrophages, are not able to efficiently clear the debris. If the clearance of debris is 
impaired, apoptotic tumor cells can stimulate the release of pro-inflammatory cytokines 
by macrophages, thus exacerbating the inflammatory response8. The accumulation of 
debris can be a result of externalized PS that functions as a way for apoptotic tumor cells 
to evade immune detection and prevent immune activation. A PS antagonist that blocks 
the pro-inflammatory signal from debris allowing for the resolution of inflammation may 
inhibit tumor growth.  
 
 Our studies demonstrate that CHOP chemotherapy induces both immunogenic 
(doxorubicin) and non-immunogenic (vincristine, mafosfamide, and prednisolone) cell 
death. Mafosfamide, vincristine, and prednisolone-generated EL4 tumor cell debris 
stimulates tumor growth at both low (1,3x105 dead cells) and high (9x105 dead cells) 
inoculum in a dose-dependent manner when the dead and living tumor cells were co-
injected into the mice. Intriguingly, we show that steroids can also generate tumor-
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promoting debris, potentially providing a mechanism by which steroids increase the risk 
of cancer, including lymphoma58.  By contrast, the high inoculum of doxorubicin-
generated dead cells significantly inhibited the growth of 1x105 living EL4 tumor cells. 
This result suggests that the optimal inhibitory outcome of doxorubicin-generated EL4 
tumor cell debris is attained at 1:9 ratio or lower of EL4 living tumor cells: doxorubicin-
generated debris. The immunogenic cell death model mimics the use of debris-associated 
antigens that stimulate host anti-tumor immunity (.i.e. cancer vaccine). Our results show 
that stimulatory activity of doxorubicin-generated debris a low inoculum (1x105 dead 
cells) can be mitigated with systemic treatment of doxorubicin-generated EL4 tumor cell 
debris.  
 
 Macrophages exposed to debris generated by mafosfamide, vincristine, and 
prednisolone secreted critical multiple pro-inflammatory and pro-tumorigenic cytokines 
and chemokines, including sICAM-1/CD54, CCL2/MCP-1, MIP-2/CXCL2, 
RANTES/CCL5 and TNF-α. This suggests that CHOP chemotherapy-generated EL4 
tumor cell debris induces inflammation that stimulates tumor growth and progression.  In 
contrast, doxorubicin-generated debris stimulated the secretion of the anti-inflammatory 
and anti-tumorigenic IL-1ra by macrophages. In fact, current clinical cancer trials are 
focused on the recombinant synthetic analog of IL-1ra (i.e. anakinra)17. 
 
  During normal physiological apoptosis, PS serves as a key immunosuppressive 
signal that prevents activation of immune system and allows silent phagocytosis of dead 
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cells. However when tumor cells hijack this mechanism, it allows them to avoid immune 
detection. Our results indicate that blocking PS on doxorubicin-generated immunogenic 
debris with Annexin V diminishes the stimulatory effect of low inoculum of debris 
(1x105 dead cells) and reverses the inhibitory effect of medium inoculum of debris (3x105 
dead cells). The same results were attained when doxorubicin-generated debris was 
treated with anti-PS antibody. This confirms that PS plays a key role on the stimulatory 
and inhibitory activity of debris. Ongoing experiments are underway in our laboratory to 
identify the key PS receptors that critically mediate CHOP chemotherapy regulation of 
tumor growth.  
 
Cytotoxic cancer therapy generates tumor stimulatory debris and inevitably 
allows certain tumor cells to survive; thus therapy aimed at killing tumor cells is a 
doubled-edged sword. This may be especially relevant in patients with dormant or 
residual tumors, as modeled by the subthreshold inoculum tumors. Our results suggest 
that CHOP chemotherapy-generated debris can promote or inhibit tumor growth 
depending on the specific chemotherapy drug and amount of debris. Harnessing the 
potential anti-tumorigenic activity of immunogenic cell debris or stimulating the 
clearance of non-immunogenic cell debris via anti-PS therapy may serve as a novel 
mechanism to inhibit tumor growth and prevent recurrence. 	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